Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. (HBIO) covers events occurring on May 17, 2022, specifically the Company's 2022 Annual Meeting of Stockholders. The filing details the outcomes of four proposals submitted to shareholders, including director elections, auditor ratification, an amendment to the Employee Stock Purchase Plan (ESPP), and executive compensation approval.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results rather than financial performance data.
Material Changes and Voting Results
Material changes reported include the election of new directors and the approval of an ESPP amendment. The specific voting results were as follows:
- Proposal 1 (Election of Directors): James W. Green and Bertrand Loy were elected as Class I Directors for a three-year term.
- James W. Green: 26,568,577 votes for; 2,399,395 votes withheld.
- Bertrand Loy: 25,938,864 votes for; 3,029,108 votes withheld.
- Proposal 2 (Auditor Ratification): Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 35,222,172
- Votes Against: 18,231
- Votes Abstained: 7,791
- Proposal 3 (ESPP Amendment): Shareholders approved an amendment to increase the number of authorized shares available for issuance by 500,000 shares.
- Votes For: 28,447,136
- Votes Against: 480,399
- Votes Abstained: 40,437
- Proposal 4 (Executive Compensation): The compensation of named executive officers was approved via a non-binding advisory vote.
- Votes For: 28,207,616
- Votes Against: 386,085
- Votes Abstained: 374,271
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The document serves strictly to report the results of the Annual Meeting and the adoption of the amended ESPP.
Investor Verification Checklist
- Verify the full text of the amended Employee Stock Purchase Plan (Exhibit 10.1) to understand the specific terms of the 500,000 share increase.
- Confirm the tenure of the newly elected Class I Directors (James W. Green and Bertrand Loy) extends until the 2025 annual meeting.
- Review the definitive proxy statement filed on April 7, 2022, for detailed descriptions of the proposals referenced in this filing.
- Note that the filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.